The oral route is a preferred method of drug administration, though achieving effective drug
delivery and minimizing off-target side effects is often challenging. Formulation into …

Amphotericin B (AmB) is a crucial agent in the management of serious systemic fungal
infections. In spite of its proven track record, its well-known side effects and toxicity will …

The sole objective of pharmaceutical science is to design successful dosage forms which
fulfill the therapeutic needs of the patients effectively. Development of new drug entities is …

Amphotericin B (AmB) loaded polymer lipid hybrid nanoparticles (AmB-PLNs) comprised of
lecithin (anionic lipid) and gelatin (Type A, cationic below its isoelectric point 7.0–9.0) were …

Amphotericin B (AmB) remains the “gold standard” for systemic antifungal therapy, even
though new drugs are emerging as the attractive antifungal agents. Since AmB has …

The oral route of protein and peptide drugs has been a popular method of drug delivery in
recent years, although it is often a challenge to achieve effective drug release and minimize …

Parenteral amphotericin B has been considered as first-line therapy in the treatment of
systemic fungal and parasitic infections, however its use has been associated with a number …

The oral administration of amphotericin B (AmB) has the major drawback of poor
bioavailability. The aim of this work was to evaluate the potential of AmB-loaded cubosomes …

Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive
fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous …

The oral administration of amphotericin B (AmB) has a major drawback of poor
bioavailability. The aim of this study was to investigate the potential of glyceryl monoolein …